ClinicalTrials.gg
Status unknownNCT05207176Updated Jan 26, 2022

Study to Evaluate the Safety and PK Properties of DWP16001 in Healthy Subjects With Various Ethnicities

A Phase 1 interventional study of DWP16001 in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-26.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
19 Years to 50 Years
Sex
All
01

Study summary

An open label, single center, parallel, single and multiple oral dose study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of DWP16001 in healthy Koreans, Caucasians, and Hispanics

Read the detailed description

This study is conducted with single center, parallel design, single and repeated administration and repeated administration.

  1. Screening (28d\~ 2d) For volunteers, screening tests such as questionnaire, physical examination and clinical examination are conducted within 4 weeks (-28d\~-2d) from the date of administration of the clinical investigational drug (1d), and subjects judged to be suitable for this clinical trial are selected.
  2. Dosing and Pharmacokinetics/Pharmacodynamic Evaluators (1d to 12d) The subjects who are judged to be suitable for this clinical trial are admitted to the clinical trial center of Seoul National University Hospital in the afternoon of 1 day (-1d) before administration. In order to maintain an empty stomach for at least 10 hours before administration of clinical trial drugs, fast except for drinking water after 10 p.m.
  3. PSV (17d \~ 21d) The post-study visit is conducted on 17d to 21d, about one week after the last dosing date.
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A healthy adult between 19 and 50 years of age at the time of screening 2. Koreans, Caucasian, and Hispanics are classified according to the following criteria.
  1. Korean: A Korean ethnic group born in Korea or outside Korea who has lived abroad for 10 years and has Korean parents and grandparents.
  2. Caucasian: Born in Europe, living abroad in Europe for 10 years, Europeans with European parents and grandparents
  3. Hispanic: Subjects of Latin American races with parents and grandparents who are Latin American, having nationalities from Mexico, Puerto Rico, Cuba, Latin America, or other Spanish cultures.
  1. At the time of screening test, if the weight is more than 50.0 kg or less than 90.0 kg, the (BMI) is 18.0 kg/m\^2 or more 30.0 kg/m\^2 or less (*body mass index, kg /m\^2) = weight (kg) / [height (m)] 2) 4. In the case of female volunteers, factors such as not necessarily pregnant or lactating or surgical infertility (both difficulty tube closure, hysterectomy, both difficulty tube resection, both ovarian resection, etc.) 5. A person who has heard sufficient explanation of this clinical trial and fully understood it, voluntarily decided to participate, and agreed in writing to comply with precautions.

Exclusion criteria

Exclusion Criteria:

  1. hepatometer (severe liver disorder, etc.), kidney (severe renal disorder, etc.), nervous system, immune system, respiratory system, digestive system, endocrine system, blood • tumor, cardiovascular system (heart failure, Torsades de points, etc.), urinary system, mental system, etc.
  2. A person who has a history of or clinically significant hypersensitivity to DWP16001 and other drugs (aspirin, antibiotics, etc.), including homogeneous drugs.
  3. Those with a history of gastrointestinal diseases (gastrointestinal ulcers, gastritis, stomach cramps, gastroesophageal reflux disease, Crohn's disease, etc.) or surgery that may affect the safety and pharmacokinetic/pharmacodynamic evaluation of DWP16001 (however, simple appendicectomy, excluding hernia surgery)
  4. The person who showed the following results in the screening test. 1) Blood (SGOT), ALT (SGPT):> × 1.5 2) Creatine cleaning rate calculated through equation: \<90 mL/min 3) Serum glucose on an empty stomach: >110 mg/dL or \<70 mg/dL 4) Serum test (syphilis test, test, test, (HIV) test) results are positive factors.
  5. Those with a systolic blood pressure \<90 mmHg or >150 mmHg or diastolic blood pressure \<60 mmHg or >100 mmHg in vital signs measured in the sitting position after resting for more than 3 minutes
  6. Those who have a history of drug abuse or who have tested positive for drugs of abuse in urine screening tests
  7. Those who have taken any prescription drugs or herbal medicines within 2 weeks before the expected first dose, or have taken any over-the-counter (OTC) drugs, health functional foods, or vitamins within 1 week (however, different conditions according to the judgment of the researcher) In this reasonable case, you can participate in the clinical trial) or those who are expected to take it
  8. Those who have taken drugs that induce or inhibit drug metabolizing enzymes, such as barbiturates, within 1 month before the expected first administration date
  9. A person who participated in other clinical trials (including biological equivalence tests) and administered drugs for clinical trials within 6 months of the expected first dose date.
  10. A person who donated whole blood within 2 months prior to the expected first dose or donated ingredients within 1 month prior to the expected first dose date, or received a blood transfusion within 1 month prior to the expected first dose date.
  11. A person who is unable to drink continuously (exceeds 21 units/week, 1 unit = 10 g of pure alcohol) or to abstain from drinking during the period from 3 days before the expected first administration date to the last discharge.
  12. A current smoker (however, if he/she quit smoking three months before the expected first dose date, he/she can be selected as a test subject) or a person who cannot stop smoking during the period from the time of discharge.
  13. Those who cannot refrain from eating grapefruit (grapefruit)-containing food during the period from 3 days before the expected first administration date to the last discharge
  14. A person who continuously consumed excessive caffeine (> 5 units/day) or who cannot prohibit the intake of caffeine/caffeine-containing foods (coffee, tea (black tea, green tea, etc.), soda, coffee milk, nutritional tonic drinks, etc.) during the expected first 3 days to the last discharge.
  15. Those who cannot use an appropriate double method or medically acceptable method of contraception for themselves, their spouse, or their partner during the entire clinical trial period, and those who do not agree not to donate sperm or eggs until the relevant period

    • Medically acceptable contraceptive method

      1. The use of intrauterine devices with proven pregnancy failure rates in oneself or spouse (or partner)
      2. Use of both blocking contraception method (for men or women) and skin killer at the same time.
      3. Surgery of the person or partner (vascularization, arthroplasty/ligation, hysterectomy
  16. Those who do not meet the above selection criteria or who are judged by the researcher as unsuitable to participate in the clinical trial due to reasons other than those that fall under the exclusion criteria
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    DWP16001

    Total number of subjects: 24 (8 Korean, 8 Caucasian, and 8 Hispanic)

    Drug: DWP16001

Interventions

  • Subjects should fast except for drinking water after 10 p.m. in order to maintain a fasting state for at least 10 hours before administration. On dosing days (5d to 10d), except for 1d and 11d, breakfast can be consumed from about 1 hour after administration of the clinical trial drug. Subjects should swallow the investigational drug whole with 150 mL of water, and should not chew the drug before swallowing. Subjects should fast for 4 hours after dosing, and can drink water freely from 2 hours after dosing.

06

What researchers measure

Primary outcomes

  1. Cmax

    Cmax of plasma DWP16001

    Time frame: Single dose: 0 (pre-dose), 0.25 to 96 hours post dose on Day 1, Multi-dose: 0 (pre-dose), 0.25 to 24 hours post dose on Day 11

  2. AUClast

    AUClast of plasma DWP16001

    Time frame: Single dose: 0 (pre-dose), 0.25 to 96 hours post dose on Day 1, Multi-dose: 0 (pre-dose), 0.25 to 24 hours post dose on Day 11

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2022; primary completion for Apr 2022, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2022
First posted
Jan 26, 2022
StartEst.
Feb 14, 2022
Primary completionEst.
Apr 8, 2022
CompletionEst.
Aug 31, 2022
Last update
Jan 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05207176
Responsible party
Sponsor
First posted
Jan 26, 2022
Start date
Feb 14, 2022 (estimated)
Primary completion
Apr 8, 2022 (estimated)
Completion
Aug 31, 2022 (estimated)
Last update
Jan 26, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion